Rectify Pharmaceuticals

Executive Summary

Rectify Pharmaceuticals is a private biotechnology company pioneering a novel class of oral small molecules called Positive Functional Modulators (PFMs) that correct dysfunctional membrane proteins, specifically ATP-binding cassette (ABC) transporters. Founded in 2020 and based in Cambridge, MA, the company targets the root cause of serious diseases by restoring transporter function. Its lead program is in primary sclerosing cholangitis (PSC), a rare liver disease with no approved therapies, and is currently in Phase 1 clinical development. Additional preclinical programs address cardio-renal-metabolic and neurological indications. The PFM platform offers a disease-modifying approach distinct from traditional symptomatic treatments, with potential for broad applicability across multiple transporter-related disorders. Key risks include early-stage clinical data, regulatory hurdles, and competition from other modalities. The company is privately held, limiting public investment avenues, but its innovative platform and high unmet need in PSC position it for potential partnership or financing milestones.

Upcoming Catalysts (preview)

• H2 2026Phase 1 clinical data readout for lead PSC program40% success
• 2027IND filing for second program (cardio-renal-metabolic or neurological)50% success
• 2026Potential strategic partnership or Series B/C financing60% success